GlassScriptPhysician profile
Christopher D Repetsky
NPI 1437619038
$2,528.72
in general payments reported to CMS, 2019-2025
28 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.08 · 2023: $669 · 2024: $775 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.63 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $238.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $165.22 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $146.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $117.70 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $100.89 | 2023-2024 | |
| Dynavax Technologies Corporation | $95.90 | 2023-2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $77.38 | 2023-2025 | Rexulti, Jynarque |
| Phathom Pharmaceuticals, INC. | $77.37 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $76.88 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $71.84 | 2023-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $59.35 | 2023-2024 | |
| Corcept Therapeutics | $56.42 | 2023-2025 | Korlym |
| Sumitomo Pharma America, INC. | $54.48 | 2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.17 | 2023-2025 | Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $33.34 | 2024-2025 | Gvoke Hypopen |
| Abbott Laboratories | $31.83 | 2025 | Freestyle Libre 3 |
| Optinose US, INC. | $27.30 | 2025 | |
| Gilead Sciences, INC. | $27.19 | 2025 | |
| Inspire Medical Systems, INC. | $22.24 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $20.38 | 2025 | Xhance, Nuzyra |
| Amgen INC. | $20.00 | 2025 | Krystexxa |
| Axsome Therapeutics, INC. | $19.57 | 2025 | Auvelity |
| Shield Therapeutics INC | $18.83 | 2024 | |
| Ibsa Pharma INC. | $18.44 | 2022 | |
| Merck Sharp & Dohme LLC | $14.40 | 2023 | Gardasil 9, Vaxneuvance |
| Vertex Pharmaceuticals Incorporated | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Repetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.